Single-cell RNA sequencing identifies the prolactin receptor as a therapeutic target in adenomyosis.

These findings establish PRL signaling as a critical driver of adenomyosis pathogenesis, highlighting PRLR inhibition as a promising therapeutic strategy and demonstrating the translational potential of HMI-115 for treating adenomyosis, a gynecological condition that has long been neglected in drug development.

Countstar (model not specified) provided cell-count and viability measurements for single-cell suspensions during preparation for single-cell or single-nucleus analysis.